We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy


THE IMPORTANCE of ongoing investigation
Our Molecular Oncology Laboratory runs innovative translational cancer research programs with the goal of generating a new framework of cancer therapy based on personalized diagnostic models, and incorporating this strategy into daily clinical practice.
R+D Biomarker Discovery
Our aim is to elucidate the role genes play in cancer development and use this knowledge to improve patient care by identifying novel theranostic biomarkers. We focus on validation of new gene signatures predictive of response to adjuvant and neoadjuvant treatment.
Drug Development
Despite advances in recent years with the use of targeted therapies, the prognosis for many cancers remains poor, often due to development of resistance to drugs. Therefore, the development of next-generation cancer therapeutics is a high priority. Thanks to our capabilities in drug discovery and early stage development, we have established collaborations with many leading experts in different fields. We screen new chemical entities obtained from existing libraries of compounds or modelled in silico against the targets of interest to profile activity.

R+D Diagnostics
Our innovative R+D Diagnostics program focuses on the development of novel molecular diagnostic tools specifically designed to detect biomarkers in clinical use. Using standard techniques, we focus on development of new assays to detect validated biomarkers such as EGFR, ALK, ROS, BRCA1, BRAF and others.
‘Liquid Biopsy’ Program
We are leaders in the field of non-invasive diagnostic tests using alternative biosources such as cerebrospinal fluid or serum, plasma and platelets from blood samples. In certain types of cancer such as lung cancer, insufficient tumor tissue obtained by traditional biopsy can mean it is not possible to perform vital diagnostic tests. Our blood tests not only overcome this difficulty, but also permit real time monitoring of the disease and early detection of resistance. Our assays have the required sensitivity and specificity for immediate incorporation into clinical practice.

As an example of our capabilities in this field, we have developed highly sensitive and specific techniques with clinical applications for the detection of genetic alterations in blood of lung cancer patients.